Kruszewski Jerzy
Klinika Chorób Infekcyjnych i Alergologii, Wojskowy Instytut Medyczny w Warszawie.
Otolaryngol Pol. 2009 Sep;63(7):5-10. doi: 10.1016/S0030-6657(09)70180-5.
The following paper reviews the latest news on antihistamines used in the treatment of allergic rhinitis. It describes the new results of investigations on clinical application of H3 and H4 receptors in therapy of allergic diseases as well as the effect of emedastine on histamine-induced tissue remodeling. Contemporary clinical research of these drugs fulfills the requirements of placebo-controlled trials, including the comparison with a reference drug, usually cetirizine. The paper discusses efficacy and safety of a new drug--bilastine, and the possibility to improve clinical outcome by combining antihistamine drugs with inhaled glucocorticosteroids and antileukotrienes. It also presents the studies on high efficacy of nasal antihistamines, which most probably results from their high concentration in inflamed tissue, as well as describes the latest news on safe use of antihistamines, including studies of fexofenadine enantiomers in drug interactions with P-glycoprotein, safety of a new antihistamine medication--rupatadine, and psychostimulating effect of some other antihistamines. The review shows that antihistamines, the most frequently used class of anti-allergy medications, have been constantly improved, which is of significant importance for progress of allergic diseases treatment.
以下论文回顾了用于治疗过敏性鼻炎的抗组胺药的最新消息。它描述了H3和H4受体在过敏性疾病治疗中的临床应用研究的新结果,以及依美斯汀对组胺诱导的组织重塑的影响。这些药物的当代临床研究符合安慰剂对照试验的要求,包括与参比药物(通常为西替利嗪)进行比较。本文讨论了一种新药——比拉斯汀的疗效和安全性,以及将抗组胺药与吸入性糖皮质激素和抗白三烯药物联合使用以改善临床疗效的可能性。它还介绍了关于鼻用抗组胺药高效性的研究,这很可能是由于它们在炎症组织中的高浓度所致,同时描述了抗组胺药安全使用的最新消息,包括非索非那定对映体与P-糖蛋白药物相互作用的研究、一种新型抗组胺药物——卢帕他定的安全性,以及其他一些抗组胺药的精神刺激作用。该综述表明,抗组胺药作为最常用的一类抗过敏药物,一直在不断改进,这对过敏性疾病治疗的进展具有重要意义。